SAN JOSE, Calif., March 4, 2020 /PRNewswire/ -- Aridis
Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company
focused on the discovery and development of novel anti-infective
therapies to treat life-threatening bacterial infections, is
pleased to provide an update on its Investor Day being held on
Thursday, March 12th, 2020
in New York City from 12:00PM-2:00PM EDT.
Featured moderators and speakers include:
- Steven Opal, MD, Clinical
Professor of Medicine, Infectious Disease Division, Brown University (Brown Medical School)
- Lisa Saiman, MD, MPH, Professor
of Pediatrics at Columbia University
Medical Center (CUMC)
- Joe Pinto, Executive Director of
Pharmacy Operations, Mount Sinai Health System
- Louise Chen, Managing Director,
Cantor Fitzgerald
- Jason McCarthy, PhD, Senior
Managing Director, Maxim Group
Key agenda topics:
- Update on Aridis' programs AR-301 for the treatment of
ventilator associated pneumonia (VAP) and AR-501, an inhalable
therapy for chronic lung infections in CF patients
- Panel discussions on the therapeutic landscape for acute
pneumonia and cystic fibrosis (CF)
- Infectious disease pricing and medical reimbursement policy
overview
- Government initiatives to enhance the development of novel
therapeutics
- Presentation of APEXTM, Aridis' cutting-edge
antibody discovery and production platform
"Aridis is part of a new generation of anti-infective companies
developing novel therapeutics for life threatening diseases whereby
superiority studies are the threshold for success. As such, it is a
pleasure to host this forum to provide investors a better
understanding of where the overall infectious disease treatment
landscape (including drug pricing and reimbursement) is headed and
in particular, the significant game-changing treatments for CF and
pneumonia will play in the patient experience and medical
community," commented Vu Truong,
Ph.D., Chief Executive of Aridis Pharmaceuticals.
Aridis is advancing AR-301 in a global clinical trial which
remains on track to report top line data in 1H 2021, and enrolling
AR-501's Phase 1/2a clinical trial with top-line data expected in
1H 2020 (healthy subjects), and in 2H 2021 (CF patients).
To learn more about the event or to register for attendance,
please email RSVP@aridispharma.com.
About Aridis Pharmaceuticals, Inc.
Aridis
Pharmaceuticals, Inc. discovers and develops anti-infectives to be
used as add-on treatments to standard-of-care antibiotics. The
Company is utilizing its proprietary APEXTM and MabIgX®
technology platforms to rapidly identify rare, potent
antibody-producing B-cells from patients who have successfully
overcome an infection, and to manufacture mAbs for therapeutic
treatment of critical infections. These mAbs are already of human
origin and functionally optimized for high potency by the donor's
immune system; hence, they do not require genetic engineering or
further optimization to achieve full functionality.
The Company has generated multiple clinical stage mAbs targeting
bacteria that cause life-threatening infections such as
VAP and HAP. The use of mAbs as anti-infective treatments
represents an innovative therapeutic approach that harnesses the
human immune system to fight infections and is designed to overcome
the deficiencies associated with the current standard of care which
is broad spectrum antibiotics. Such deficiencies include, but are
not limited to, increasing drug resistance, short duration of
efficacy, disruption of the normal flora of the human microbiome
and lack of differentiation among current treatments. The mAb
portfolio is complemented by a non-antibiotic novel mechanism small
molecule anti-infective candidate being developed to treat lung
infections in cystic fibrosis patients. The company's pipeline is
highlighted below:
Aridis' Pipeline
AR-301 (VAP). AR-301
is a fully human immunoglobulin 1, or IgG1, mAb currently in Phase
3 clinical development targeting gram-positive S.
aureus alpha-toxin in VAP patients.
AR-101 (HAP). AR-101 is a fully human
immunoglobulin M, or IgM, mAb targeting P.
aeruginosa liposaccharides serotype O11, which accounts
for approximately 22% of all P.
aeruginosa hospital acquired pneumonia cases
worldwide.
AR-501 (cystic fibrosis). AR-501 is an inhaled
formulation of gallium citrate with broad-spectrum anti-infective
activity being developed to treat chronic lung infections in cystic
fibrosis patients. This program is currently in a Phase 1/2a
clinical study in healthy volunteers and CF patients.
AR-401 (blood stream infections). AR-401 is a
fully human mAb preclinical program aimed at treating infections
caused by gram-negative Acinetobacter baumannii.
AR-201 (RSV infection). AR-201 is a fully human IgG1
mAb preclinical program aimed at neutralizing diverse clinical
isolates of respiratory syncytial virus (RSV).
For additional information on Aridis Pharmaceuticals, please
visit https://aridispharma.com/.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These statements may be
identified by the use of words such as "anticipate," "believe,"
"forecast," "estimated" and "intend" or other similar terms or
expressions that concern Aridis' expectations, strategy, plans or
intentions. These forward-looking statements are based on Aridis'
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events
to differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to,
the timing of regulatory submissions, Aridis' ability to obtain and
maintain regulatory approval of its existing product candidates and
any other product candidates it may develop, approvals for clinical
trials may be delayed or withheld by regulatory agencies, risks
relating to the timing and costs of clinical trials, risks
associated with obtaining funding from third parties, management
and employee operations and execution risks, loss of key personnel,
competition, risks related to market acceptance of products,
intellectual property risks, risks associated with the uncertainty
of future financial results, Aridis' ability to attract
collaborators and partners and risks associated with Aridis'
reliance on third party organizations. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various important factors, including, without limitation, market
conditions and the factors described under the caption "Risk
Factors" in Aridis' 10-K for the year ended December 31, 2018 and Aridis' other filings
made with the Securities and Exchange
Commission. Forward-looking statements included herein are
made as of the date hereof, and Aridis does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.
Contact:
Investor Relations
Jason Wong
Blueprint Life Science Group
jwong@bplifescience.com
(415) 375-3340 Ext. 4
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aridis-pharmaceuticals-provides-update-on-investor-day-featuring-key-opinion-leader-panels-on-cystic-fibrosis-and-pneumonia-301015918.html
SOURCE Aridis Pharmaceuticals, Inc.